Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

185
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
185
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

361
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
361
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

689
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
689
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

600
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
600
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

588
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
588
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

2.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.

BMC medicine·2020
Same author

Role of <i>Helicobacters</i> in Neuropsychiatric Disease: A Systematic Review in Idiopathic Parkinsonism.

Journal of clinical medicine·2020
Same author

Constructing Approaches to Entrustable Professional Activity Development that Deliver Valid Descriptions of Professional Practice.

Teaching and learning in medicine·2020
Same author

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.

Therapeutic advances in psychopharmacology·2020
Same author

Bio-inspired protective structures for marine applications.

Bioinspiration & biomimetics·2020
Same author

Clozapine and COVID-19: The authors respond.

Journal of psychiatry & neuroscience : JPN·2020
Same journal

The Clinical Threshold for Treatment in Psychiatry.

JAMA psychiatry·2026
Same journal

Semaglutide in Schizophrenia-A Top Clinical Trial.

JAMA psychiatry·2026
Same journal

Adolescent Peers' Diagnoses and Genetic Predispositions and Subsequent Risk of Mental Disorders.

JAMA psychiatry·2026
Same journal

Use and Misuse of GLP-1 Receptor Agonists Among People With Eating Disorders.

JAMA psychiatry·2026
Same journal

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

JAMA psychiatry·2026
Same journal

Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.

JAMA psychiatry·2026
See all related articles

Related Experiment Video

Updated: Dec 12, 2025

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.7K

Tapering Antipsychotic Treatment

Mark Abie Horowitz1,2, Robin M Murray3, David Taylor3,4

  • 1Division of Psychiatry, University College London, London, United Kingdom.

JAMA Psychiatry
|August 11, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression
07:00

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression

Published on: January 23, 2017

24.6K

Related Experiment Videos

Last Updated: Dec 12, 2025

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.7K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression
07:00

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression

Published on: January 23, 2017

24.6K